GLP-1 Compound Legislation: States are the Next Battlefield w/ Sabina Hemme

Pharma Influence & Why Patient Voices Matter Lobbying Power: Eli Lilly, Novo Nordisk, and Government Access Why GLP-1 Medication Access Is at Risk Introducing Sabina Hemi & the Mission of GLP Winner Why Compounded GLP-1s Matter for Real Patients The Federal “Safe Drugs” Bill: What It Claims vs What It Does Why This Bill Raises Red Flags for Patients What Real Compounding Safety Reform Would Look Like How Compounding Pharmacies Are Actually Regulated Today Prescription Reporting vs Patient Safety Is This Bill About Safety or Litigation Data? Dose Flexibility, Personalized Medicine, and Compounding Florida SB 860: A Direct Threat to Compounded GLP-1s Why Florida Compounding Impacts the Entire Country Why Obesity Medications Are Being Singled Out Active Pharmaceutical Ingredients (API): What Patients Should Know FDA Oversight, the “Green List,” and State Overreach Why Florida’s API & COA Requirements Don’t Add Up FDA Inspection Backlogs & Impossible Compliance Standards Branded Drug Safety Issues vs Compounding Scrutiny Catalent, Novo Nordisk, and Manufacturing Concerns Counterfeit Ozempic: The Overlooked Safety Crisis Why Supply Chain Integrity Should Be the Priority What Patients Can Do Right Now Petitions, Advocacy, and Making Your Voice Heard Florida Residents: Why Local Action Matters Final Thoughts on Access, Power, and Patient Advocacy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.